Amgen 2009 Annual Report Download - page 175
Download and view the complete annual report
Please find page 175 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165 -
166 -
167 -
168 -
169 -
170 -
171 -
172 -
173 -
174 -
175 -
176 -
177 -
178 -
179 -
180
 |
 |
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
21. Segment information
We operate in one business segment — human therapeutics. Therefore, results of our operations are reported
on a consolidated basis for purposes of segment reporting, consistent with internal management reporting.
Enterprise-wide disclosures about product sales, revenues and long-lived assets by geographic area, and revenues
from major customers are presented below.
Revenues
Revenues consisted of the following (in millions):
Years ended December 31,
2009 2008 2007
Product sales:
Aranesp®— U.S. ................................................. $ 1,251 $ 1,651 $ 2,154
Aranesp®— International .......................................... 1,401 1,486 1,460
EPOGEN®— U.S. ................................................ 2,569 2,456 2,489
Neulasta®— U.S. ................................................. 2,527 2,505 2,351
NEUPOGEN®— U.S. ............................................. 901 896 861
Neulasta®— International .......................................... 828 813 649
NEUPOGEN®— International ...................................... 387 445 416
ENBREL — U.S. ................................................. 3,283 3,389 3,052
ENBREL — Canada .............................................. 210 209 178
Sensipar®— U.S. ................................................. 429 412 333
Sensipar®— International .......................................... 222 185 130
Other — U.S. .................................................... 175 151 203
Other — International ............................................. 168 89 35
Total product sales .............................................. 14,351 14,687 14,311
Other revenues ..................................................... 291 316 460
Total revenues ................................................. $14,642 $15,003 $14,771
Geographic information
Outside the United States, we principally sell Aranesp®, Neulasta®and NEUPOGEN®in Europe and EN-
BREL in Canada only. Information regarding revenues and long-lived assets (consisting of property, plant and
equipment) attributable to the United States and to all international countries collectively is stated below. The
geographic classification of product sales was based upon the location of the customer. The geographic classi-
fication of all other revenues was based upon the domicile of the entity from which the revenues were earned.
F-55